GRANGE DAVID L 4
4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Nov 4, 2010
Insider Transaction Report
Form 4
GRANGE DAVID L
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Common Stock
2010-11-02$21.98/sh+373$8,199→ 61,418 total - Sale
Common Stock
2010-11-02$26.00/sh−373$9,698→ 61,045 total - Exercise/Conversion
Stock Options (to buy)
2010-11-03−51,380→ 155,259 totalExercise: $21.98From: 2010-07-01Exp: 2019-07-01→ Common Stock (51,380 underlying) - Sale
Common Stock
2010-11-03$25.71/sh−51,380$1,320,980→ 61,045 total - Exercise/Conversion
Stock Options (to buy)
2010-11-02−373→ 206,639 totalExercise: $21.98From: 2010-07-01Exp: 2019-07-01→ Common Stock (373 underlying) - Exercise/Conversion
Common Stock
2010-11-03$21.98/sh+51,380$1,129,332→ 112,425 total
Holdings
- 50,000
Stock Options (to buy)
Exercise: $26.64From: 2011-06-17Exp: 2020-06-17→ Common Stock (50,000 underlying) - 103,506
Stock Options (to buy)
Exercise: $20.45From: 2011-02-25Exp: 2020-02-25→ Common Stock (103,506 underlying) - 6,485
Stock Options (to buy)
Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying)
Footnotes (5)
- [F1]50,000 shares of restricted stock were granted upon the Reporting Person's acceptance of employment as Chief Executive Officer. These shares vest in four equal increments on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.
- [F2]The price shown is a weighted average; the shares were sold at prices ranging from $25.70 to $25.77. Upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
- [F3]The options vest in three equal installments on 6/17/11, 6/17/12 and 6/17/13.
- [F4]The options vest in three equal installments on 2/25/11, 2/25/12 and 2/25/13.
- [F5]The options vest in four equal installments of 50,000 on 7/1/10, 7/1/11, 7/1/12 and 7/1/13.